Stopping Empagliflozin Unmasks Heart Failure

Fed Pract. 2021 Nov;38(Suppl 4):e44-e45. doi: 10.12788/fp.0144.

Abstract

SGLT2 inhibitors have been shown to have a role in the management of heart failure in patients with type 2 diabetes mellitus, but there is a risk of exacerbation when discontinued.